| Previous Close | 7.50 |
| Open | 7.51 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1400 |
| Day's Range | 7.13 - 7.55 |
| 52 Week Range | 6.28 - 310.90 |
| Volume | 59,159 |
| Avg. Volume | 125,695 |
| Market Cap | 656.029M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.94 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.00 |
Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2019 financial results will be reported before the market opens on Friday, May 10. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
CANTON, Mass., April 01, 2019 -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture.
CANTON, Mass. , March 18, 2019 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and.
CANTON, Mass., March 14, 2019 /PRNewswire/ -- Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced a new credit agreement with Silicon Valley Bank, the lead agent, and MidCap Financial. The agreement provides for a credit facility in the aggregate principal amount of $100 million, consisting of a $60 million term loan facility and a $40 million revolving credit facility. The agreement contains customary representations, warranties, and covenants, including financial covenants, and requires achievement of certain financial milestones in order to draw the final $20 million of the term loan facility. The proceeds from the term loan and revolving credit facility will be used for general corporate purposes and the repayment of the Company's existing credit facility and a lease with Eastward Capital Partners.
Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that clinical trial results demonstrating the effectiveness of ReNu® in treating symptoms associated with knee osteoarthritis (OA) will be presented this week by Jack Farr, MD, Medical Director of the Cartilage Research Center of Indiana at the American Academy of Orthopedic Surgeons’ AAOS 2019 Annual Meeting, held March 12-16 in Las Vegas. Dr. Farr, the principal investigator of the study, will present on the study methodology and findings during a March 14 paper presentation. ReNu is a cryopreserved, amniotic suspension allograft, derived from human amnion and amniotic fluid.
CANTON, Mass., March 11, 2019 -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and.
Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that a new case series published in Plastic and Reconstructive Surgery - Global Open suggests PuraPly® Antimicrobial (PuraPly AM) positively affects the course of healing in a variety of complex, chronic wounds that were previously unresponsive to treatment. The case series, “Use of Native Type I Collagen Matrix Plus Polyhexamethylene Biguanide for Chronic Wound Treatment” was conducted by Alisha R. Oropallo, MD, FACS, APWCA, et al, of Northwell Health Department of Surgery in Lake Success, New York.
Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2018 financial results will be reported after the market closes on Monday, March 18.
Organogenesis Holdings Inc. (ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, will sponsor a January 30 WoundSource webinar, “Chronic Wounds and Biofilms: Advancing Assessment and Treatment” led by Gregory Schultz, PhD, Professor of Obstetrics and Gynecology and Director of the Institute for Wound Research at the University of Florida. The webinar will also address the concept of Biofilm-Based Wound Care and the STEP-DOWN-THEN-STEP-UP approach for effective therapies in treating chronic wounds. An important voice in the field of biotechnology and regenerative medicine, Dr. Schultz is a former president of the Wound Healing Society and co-author of more than 400 scientific publications.
ORGOW) today announced that on January 4, 2019, the Company was notified by The Nasdaq Stock Market LLC ("Nasdaq") that, based on the plan of compliance presented by the Company at its hearing, the Nasdaq Hearings Panel (the "Panel") has granted the Company's request for the continued listing of its Class A common stock on The Nasdaq Capital Market. Pursuant to the Panel's decision, on or before March 31, 2019, the Company is required to demonstrate to the satisfaction of Staff and the Panel that it has a minimum of 300 round lot shareholders of its Class A common stock and that it otherwise meets all applicable requirements for listing on Nasdaq.
NEW YORK, Jan. 07, 2019 -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading in Organogenesis Holdings Inc. (Nasdaq: ORGO) is scheduled to resume on Tuesday,.